HOME >> MEDICINE >> NEWS
Misdosing common for powerful anti-clotting drugs

Because of inaccuracies in prescribing, 42 percent of patients rushed to emergency rooms with symptoms of a heart attack received doses of powerful drugs intended stop clotting in coronary arteries outside of the recommended range, a new analysis by Duke Clinical Research Institute (DCRI) cardiologists has found.

While numerous clinical trials have proven that these drugs can save lives, correct dosing is crucial, the researchers said, since the therapeutic window is narrow. Too much of the drug can lead to bleeding episodes, while too little may be ineffective at stopping the clotting process.

The Duke researchers believe that when evaluating these patients in emergency rooms, physicians should spend a little more time clarifying information such as weight and kidney function which are necessary for accurate dosing. The researchers also hope that the results of their analysis provide concrete steps to improve safety thereby increasing physician confidence in using these drugs on high risk patients, who have the most to gain.

"These drugs are clearly beneficial, and when dosed correctly, are also safe," said Duke cardiologist Karen Alexander, M.D., lead investigator of the study published Dec. 28, 2005, in the Journal of the American Medical Association.

The drugs in question unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and glycoprotein IIb/IIIa inhibitors work by either preventing the aggregation of platelets in coronary arteries or interfering with the formation of blood clots. The drugs are typically given within the first 24 hours of heart attack symptoms, and it is not uncommon for patients to receive combinations of these drugs during their hospital stay. Doses are determined by patient-specific data incorporated into standard prescribing algorithms.

"Our analysis, which includes patients treated in all types of hospitals across the country shows that dosing errors occur more often in vulnerabl
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
27-Dec-2005


Page: 1 2 3

Related medicine news :

1. Refusal of medical and surgical interventions common among chronically ill elderly
2. Needle-stick injuries are common but unreported by surgeons in training
3. Sleep-related breathing disorder common among aggressive, bullying schoolchildren
4. Nearly half of children in Kenya with common type of severe malaria affected neurologically
5. Scientists identify cells responsible for relapse after treatment in common childhood cancer
6. Infection detectives use disease fingerprints to track common infections in children
7. Anxiety disorders surprisingly common yet often untreated
8. Mental illnesses appear common among veterans returning from Iraq and Afghanistan
9. Sleep apnea common, but undiagnosed, among pacemaker patients
10. Use of common pain relievers associated with increased risk of blood pressure in men
11. Updated rates of common US neurological disorders

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Misdosing common for powerful anti clotting drugs

(Date:3/5/2015)... Southlake, TX (PRWEB) March 05, 2015 ... an in-office, non-surgical treatment for OB-GYNs and Urogynecologists. ... system, used for non-surgical dermatological application in aesthetics ... pleased to have a non-invasive, in-office procedure, and ... for women who want results without surgery. ThermiVa ...
(Date:3/5/2015)... Building on its commitment to provide ... The Academy of Oncology Nurse & Patient Navigators (AONN+) ... voice ™ (CONQUER ™). , “Cancer has ... and their loved ones each year,” says Pam Rattananont ... ever, there is a need in the oncology space ...
(Date:3/4/2015)... MyCpapStore.com, an online provider of CPAP equipment ... quality products designed to remedy the problem of snoring. ... merchandise from name-brand manufacturers, giving its customers access to ... Sleep apnea is a common condition affecting people of ... restricted airflow. The CPAP (continuous positive airway pressure) machine ...
(Date:3/4/2015)... Vegas, NV (PRWEB) March 04, 2015 In ... as the fight that is the main event. For ... and that fight will be for the UFC Featherweight Championship. ... the brash, often out-spoken native of Ireland, Conor “Notorious” McGregor. ... MGM Grand Garden Arena in Las Vegas, NV. , When ...
(Date:3/4/2015)... Dr. Christopher Asandra, M.D., Founder and Chief ... lamented the FDA’s recent decision to issue a ... that FDA’s conclusions are not supported by science, and ... testosterone deficiency. , “The FDA appears to have developed ... said Dr. Asandra. “There is not nearly enough evidence ...
Breaking Medicine News(10 mins):Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 3Health News:The Academy of Oncology Nurse & Patient Navigators Launches CONQUER: the patient voice™ to Help Meet the Informational Needs of Patients with Cancer 2Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... Texas , March 4, 2015 ... II pilot study in patients with moderate to ... Dermatology. The open-label Phase II trial evaluated the ... monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a ... inflammatory cells present in skin lesions. The Company ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
Cached News: